Company Profile

Mesoblast Limited

Level 1, 843A Glenhuntly Road

Caulfield South VIC 3162 Australia
Phone: 03-9618-7000 Fax:

Industry
Biotechnology

Segment
Research and Development

Company News

Mesoblast (MSB.AX) Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial 7/1/2016 9:17:18 AM

Mesoblast (MSB.AX) Stock Sinks 42% After Teva (TEVA) Withdraws from Heart Failure Trials 6/14/2016 6:42:01 AM

Mesoblast (MSB.AX) Provides Strategic Update And Reports On First Quarter Financial Results 12/17/2015 8:03:54 AM

Mesoblast (MSB.AX)’s Japan Licensee Receives Pricing For TEMCELL HS Inj. For Treatment Of Acute Graft Versus Host Disease 11/30/2015 7:19:20 AM

Mesoblast (MSB.AX) Lists On Nasdaq 11/16/2015 7:58:00 AM

Mesoblast (MSB.AX) Announces Pricing Of Public Offering On Nasdaq 11/13/2015 7:22:41 AM

Mesoblast (MSB.AX) Release: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions 10/28/2015 7:21:02 AM

Mesoblast (MSB.AX) Chairman's Address To 2015 Annual General Meeting 10/22/2015 8:31:37 AM

Celgene (CELG) And Mesoblast (MSB.AX) Extend Agreement 10/16/2015 7:48:56 AM

//-->